Zobrazeno 1 - 10
of 407
pro vyhledávání: '"Yoshitaka Saito"'
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract Hand-foot syndrome (HFS) is a frequently occurring and treatment-requiring adverse effect of docetaxel. We previously reported that systemic dexamethasone (DEX) prevents the other docetaxel-induced adverse inflammatory effects in a dose-depe
Externí odkaz:
https://doaj.org/article/999140ee16aa4c42b2f9448bcfbe4846
Autor:
Ayaka Igarashi, Yutaka Takezawa, Yuki Ozawa, Tomomi Saito, Hiroshi Nakayama, Takeaki Makino, Toru Etsunaga, Yoshitaka Saito, Mikio Kobayashi
Publikováno v:
IJU Case Reports, Vol 7, Iss 3, Pp 262-265 (2024)
Introduction Hand, foot, and mouth disease generally occurs in children. In rare cases, hand, foot, and mouth disease affects the testicles. Case presentation A 29‐year‐old man presented to our emergency department with testicular pain for severa
Externí odkaz:
https://doaj.org/article/7f5d1395ad8d4cefa9d0b452dc4e9665
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract Regorafenib is the first multikinase inhibitor for treating metastatic colorectal cancer (mCRC). Proteinuria is a frequently encountered adverse effect, regardless of prior administration of vascular endothelial growth factor inhibitors. Her
Externí odkaz:
https://doaj.org/article/ef8922a606a848b8932d8445f8221a70
Autor:
Ken Inada, Yoshitaka Saito, Kenji Baba, Daisuke Fukui, Yuriko Masuda, Sachie Inoue, Takahiro Masuda
Publikováno v:
BMC Psychiatry, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Background Premature mortality, frequent relapse that easily leads to hospitalization, and discontinuous employment are key challenges for the treatment of schizophrenia. We evaluated risk factors for important clinical outcomes (death, hosp
Externí odkaz:
https://doaj.org/article/4e5524a7887545479846113b8170d71a
Autor:
Yoshitaka Saito, Shinya Tamaki, Daisuke Hirate, Shinya Takada, Kenta Takahashi, Yoh Takekuma, Jun Sakakibara-Konishi, Yasushi Shimizu, Ichiro Kinoshita, Mitsuru Sugawara
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Treatment using docetaxel (DOC) and ramucirumab (RAM) is an effective regimen in second or later line advanced non-small cell lung carcinoma (NSCLC) treatment. However, it induces severe adverse effects, resulting in treatment reduction such
Externí odkaz:
https://doaj.org/article/20ad6858212c4d0fa9957704904ae48e
Autor:
Yoshitaka Saito, Masaki Kobayashi, Shinya Tamaki, Katsuyuki Nakamura, Daisuke Hirate, Kenta Takahashi, Yoh Takekuma, Jun Sakakibara-Konishi, Yasushi Shimizu, Ichiro Kinoshita, Mitsuru Sugawara
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract The occurrence of cisplatin (CDDP)-induced nephrotoxicity (CIN) has decreased with advancements in supportive care. In contrast, we reported that baseline diabetes mellitus (DM) complications significantly worsen CIN. This study aimed to det
Externí odkaz:
https://doaj.org/article/a4d3afe4b05242969140dcd10dc4d400
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Oral mucositis (OM) is a common adverse effect of docetaxel-containing treatment. This study aimed to assess whether dexamethasone (DEX) dose-dependently attenuates docetaxel-induced OM and dysgeusia. We retrospectively analyzed medical reco
Externí odkaz:
https://doaj.org/article/a917be787d4d4331a5e29d7e3f6f70d1
Autor:
Yoshitaka Saito, Ryota Kanno, Yoh Takekuma, Takashi Takeshita, Tomohiro Oshino, Mitsuru Sugawara
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Docetaxel-induced fluid retention (DIFR) cumulatively occurs and is one of the most troublesome adverse effects. This study aimed to determine whether high dose dexamethasone (DEX) could prevent DIFR during breast cancer treatment. Breast ca
Externí odkaz:
https://doaj.org/article/881e8e8c97154e808f55be54608079a7
Publikováno v:
Case Reports in Oncology, Vol 16, Iss 1, Pp 372-377 (2023)
Here, we describe a case of temporary severe neutropenia after atezolizumab monotherapy and its treatment course. Atezolizumab monotherapy was introduced as a 6th-line treatment for a man in his late 60s, who was diagnosed with stage Ⅳ lung adenoca
Externí odkaz:
https://doaj.org/article/a109e59675b74220bbf6d274e49c0237
Publikováno v:
Case Reports in Oncological Medicine, Vol 2024 (2024)
Immune checkpoint inhibitors have drastically improved cancer treatment. However, they may induce immune-related adverse events (irAEs). Here, we report a case of significantly delayed rheumatic irAEs (Rh-irAEs) with prior possible temporary neutrope
Externí odkaz:
https://doaj.org/article/573dc3aa954a4b3c9e4ca079b7bdfc86